Design: Observer-blind, randomised, placebo-controlled phase 1/2 trial
Population: 194 adults aged 18-64 with recent S. aureus skin and soft tissue infection
Primary outcome: Safety; efficacy against recurrent infection at 12 months
Effect: Vaccine efficacy -38.1% (95% CI -245.8 to 40.9); stopped for futility

A phase 1/2 trial (Clinical Infectious Diseases, 7 October 2026) gave 194 adults with a recent Staphylococcus aureus skin or soft tissue infection two doses of an adjuvanted five-antigen vaccine or placebo, two months apart, with 12 months of follow-up.

The vaccine produced strong functional antibody responses against three of its antigens, but showed no protection against recurrence (vaccine efficacy -38.1%, 95% CI -245.8% to 40.9%). Enrolment stopped when predefined futility criteria were met. Local reactions were more common with the vaccine; serious adverse events were similar.

This matters because it adds to a run of staphylococcal vaccines that raised antibodies and failed in the clinic, which suggests antibody levels are not a good stand-in for protection against this organism. For practice, prevention of recurrent boils still rests on wound care, hygiene and selective decolonisation.

Do not expect a staphylococcal vaccine for recurrent boils in the near term
Treat antibody responses to staphylococcal vaccines as poor predictors of protection
Manage recurrent infection with drainage, hygiene measures and selective decolonisation

Why it matters

It shows again that a strong antibody response against staphylococcus does not mean protection.

The statistics, in plain English

A vaccine efficacy of -38% with an interval running from -246% to +41% means the trial found no protection and cannot rule out either moderate benefit or harm; the trial was stopped early for futility, so the estimate is imprecise.